ST. JOSEPH, Mich., June 24 GeneGo, Inc., the leadingsystems biology tools company, announced today that VTT has licensedMetaCore(TM). VTT develops novel high-throughput methods for cancer research,drug discovery and diagnostics. The focus is in investigating mechanisms ofcancer development and progression, identification of therapeutic targets andexploration of the mechanism of action of anti-cancer compounds. VTT willutilize MetaCore and MetaDrug in high-throughput compound screening, RNAinterference experiments, cell biology and bioinformatics projects to identifypathways and networks important in translational cancer research.
There are 85 researchers and staff members working in VTT's MedicalBiotechnology Knowledge Centre in Turku. The research is funded by theEuropean Commission and the Academy of Finland. VTT accommodates two EU MarieCurie Centre of Excellence teams and coordinates the Academy of Finland Centreof Excellence for translational genome-wide biology. Further information onVTT: http://www.vtt.fi.
"VTT was our first customer in Finland and an important internationallyrecognized cancer research center," said Julie Bryant, GeneGo's VP of Businessdevelopment. "We have seen a growing need for analysis platforms focused indisease areas recently. We responded by developing disease pathway ontologies,biomarker and drug databases and new interactome analysis tools. We arepleased that our expertise in cancer is appreciated by professional molecularoncologists at VTT."
About GeneGo, Inc.
GeneGo, Inc. systems biology technology for life science research. Theoriginal computational MetaDiscovery(TM) platform allows an integration andexpert analysis of different kinds of experimental data (mRNA expression,proteomics, metabolomics, microRNA assays and other phenotypic data) andrelevant bioactive chemistry (metabolites, drugs, other xenobiotics) withinthe framework of curated biological pathways and networks. GeneGo's flagshipproduct, MetaCore 4.7(TM), assists pharmaceutical scientists in the areas oftarget selection and validation, identification of biomarkers for diseasestates and toxicology. The second product, MetaDrug 4.7(TM) is designed forprediction of human metabolism, toxicity and biological effects for novelsmall molecules compounds. MetaBase(TM) represents the knowledge base forMetaCore. For more information, please visit the company's web site athttp://www.genego.com
MetaCore(TM), MetaBase(TM), MetaDrug(TM), MetaLink(TM), MetaDiscovery(TM),MetaTox(TM), MetaMiner(TM) and 1-2-3 Workflow(TM) are trademarks of GeneGo,Inc.
SOURCE GeneGo, Inc.